147 related articles for article (PubMed ID: 4000717)
1. In vivo activity of a new heparinoid.
Ockelford PA; Carter CJ; Hirsh J
Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
[TBL] [Abstract][Full Text] [Related]
2. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
Meuleman DG
Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
[TBL] [Abstract][Full Text] [Related]
3. Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG
Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid.
Harenberg J; Zimmermann R; Schwarz F; Kübler W
Lancet; 1983 Apr; 1(8331):986-7. PubMed ID: 6132291
[No Abstract] [Full Text] [Related]
5. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
[TBL] [Abstract][Full Text] [Related]
6. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
Hobbelen PM; Vogel GM; Meuleman DG
Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
[TBL] [Abstract][Full Text] [Related]
7. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
[TBL] [Abstract][Full Text] [Related]
8. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis.
Rowlings PA; Mansberg R; Rozenberg MC; Evans S; Murray B
Aust N Z J Med; 1991 Feb; 21(1):52-4. PubMed ID: 1709804
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
[TBL] [Abstract][Full Text] [Related]
10. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
[No Abstract] [Full Text] [Related]
11. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.
Doherty DC; Ortel TL; de Bruijn N; Greenberg CS; Van Trigt P
Anesthesiology; 1990 Sep; 73(3):562-5. PubMed ID: 1697448
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
Leyvraz P; Bachmann F; Bohnet J; Breyer HG; Estoppey D; Haas S; Hochreiter J; Jakubek H; Mair J; Sorensen R
Br J Surg; 1992 Sep; 79(9):911-4. PubMed ID: 1422754
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid.
Henny CP; ten Cate H; ten Cate JW; Prummel MF; Peters M; Büller HR
Thromb Haemost; 1986 Apr; 55(2):301. PubMed ID: 3715796
[No Abstract] [Full Text] [Related]
15. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
[TBL] [Abstract][Full Text] [Related]
16. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.
Henny CP; Ten Cate H; Ten Cate JW; Surachno S; van Bronswijk H; Wilmink JM; Ockelford PA
Lancet; 1983 Apr; 1(8330):890-3. PubMed ID: 6132219
[TBL] [Abstract][Full Text] [Related]
17. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
Hoppensteadt D; Walenga JM; Fareed J
Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
[TBL] [Abstract][Full Text] [Related]
18. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
[No Abstract] [Full Text] [Related]
20. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.
Ten Cate H; Henny CP; Büller HR; Ten Cate JW; Magnani HN
Ann Neurol; 1984 Mar; 15(3):268-70. PubMed ID: 6721448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
